Ticker

Immunic (NASDAQ: IMUX - Get Free Report) and Neuphoria Therapeutics (NASDAQ: NEUP - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Profitability This table compares Immunic and Neuphoria Therapeutics'

Immunic Inc (NASDAQ:IMUX), a late-stage biotechnology company developing oral treatments for neurological and gastrointestinal diseases, will participate in two investor conferences this month. Chief executive Daniel Vitt and president Jason Tardio will take part in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami on 11 March, with one-on-one investor meetings also scheduled across the…

The bank now forecasts DDR contract prices rising 72% in the first quarter alone, with undersupply expected to persist into 2028 Wall Street's retreat from...

NEW YORK, March 3, 2026 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced participation in the following investor conferences in March: March 8-11: Leerink Partners Global Healthcare Conference. Daniel Vitt, Ph.D.

7.56am: IHG included in hotel competition probe  The Competition and Markets Authority has launched an investigation into Intercontinental Hotels,...